4.85 USD
+0.12 (+2.54%)
GNFT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. GNFT has a bad profitability rating. Also its financial health evaluation is rather negative. GNFT does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
GNFT had negative earnings in the past year.
In the past year GNFT has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: GNFT reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: GNFT reported negative operating cash flow in multiple years.
1.2 Ratios
GNFT has a better Return On Assets (-17.89%) than 78.46% of its industry peers.
The Return On Equity of GNFT (-73.87%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.89% | ||
| ROE | -73.87% | ||
| ROIC | N/A |
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Profit Margin of GNFT has declined.
In the last couple of years the Operating Margin of GNFT has declined.
GNFT has a better Gross Margin (95.42%) than 94.94% of its industry peers.
In the last couple of years the Gross Margin of GNFT has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for GNFT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.42% |
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
2. Health
2.1 Basic Checks
GNFT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GNFT has more shares outstanding
The number of shares outstanding for GNFT has been increased compared to 5 years ago.
The debt/assets ratio for GNFT is higher compared to a year ago.
2.2 Solvency
GNFT has an Altman-Z score of -1.41. This is a bad value and indicates that GNFT is not financially healthy and even has some risk of bankruptcy.
GNFT has a Altman-Z score (-1.41) which is in line with its industry peers.
A Debt/Equity ratio of 0.09 indicates that GNFT is not too dependend on debt financing.
GNFT's Debt to Equity ratio of 0.09 is on the low side compared to the rest of the industry. GNFT is outperformed by 62.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.41 |
ROIC/WACCN/A
WACC7.22%
2.3 Liquidity
GNFT has a Current Ratio of 3.74. This indicates that GNFT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.74, GNFT is in line with its industry, outperforming 45.88% of the companies in the same industry.
GNFT has a Quick Ratio of 3.74. This indicates that GNFT is financially healthy and has no problem in meeting its short term obligations.
GNFT's Quick ratio of 3.74 is in line compared to the rest of the industry. GNFT outperforms 48.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.74 | ||
| Quick Ratio | 3.74 |
3. Growth
3.1 Past
The earnings per share for GNFT have decreased strongly by -289.19% in the last year.
The earnings per share for GNFT have been decreasing by -70.77% on average. This is quite bad
The Revenue for GNFT has decreased by -45.94% in the past year. This is quite bad
GNFT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.61% yearly.
EPS 1Y (TTM)-289.19%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-137.74%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-43.21%
3.2 Future
Based on estimates for the next years, GNFT will show a very negative growth in Earnings Per Share. The EPS will decrease by -29.44% on average per year.
GNFT is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.86% yearly.
EPS Next Y-110.7%
EPS Next 2Y-96.29%
EPS Next 3Y-45.26%
EPS Next 5Y-29.44%
Revenue Next Year-8.28%
Revenue Next 2Y-21.93%
Revenue Next 3Y-9.85%
Revenue Next 5Y-1.86%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
GNFT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GNFT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as GNFT's earnings are expected to decrease with -45.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-96.29%
EPS Next 3Y-45.26%
5. Dividend
5.1 Amount
No dividends for GNFT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:GNFT (11/19/2025, 2:00:00 PM)
4.85
+0.12 (+2.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.76%
Inst Owner Change-19.19%
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap242.51M
Revenue(TTM)45.41M
Net Income(TTM)-38.76M
Analysts90.77
Price Target10.01 (106.39%)
Short Float %0.05%
Short Ratio1.78
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.1%
PT rev (3m)-6.92%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-109.24%
EPS NY rev (3m)-106.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.91%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.59 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.97 | ||
| P/tB | 97.95 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.81
EYN/A
EPS(NY)-0.79
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS1.06
BVpS1.22
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.89% | ||
| ROE | -73.87% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.42% | ||
| FCFM | N/A |
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
F-Score2
Asset Turnover0.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 188.46% | ||
| Cap/Sales | 7.33% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.74 | ||
| Quick Ratio | 3.74 | ||
| Altman-Z | -1.41 |
F-Score2
WACC7.22%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-289.19%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-137.74%
EPS Next Y-110.7%
EPS Next 2Y-96.29%
EPS Next 3Y-45.26%
EPS Next 5Y-29.44%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-43.21%
Revenue Next Year-8.28%
Revenue Next 2Y-21.93%
Revenue Next 3Y-9.85%
Revenue Next 5Y-1.86%
EBIT growth 1Y-216.85%
EBIT growth 3Y-53.58%
EBIT growth 5YN/A
EBIT Next Year-6.17%
EBIT Next 3Y-0.9%
EBIT Next 5YN/A
FCF growth 1Y87.25%
FCF growth 3Y-47.27%
FCF growth 5YN/A
OCF growth 1Y93.33%
OCF growth 3Y-46.21%
OCF growth 5YN/A
GENFIT-ADR / GNFT FAQ
What is the fundamental rating for GNFT stock?
ChartMill assigns a fundamental rating of 2 / 10 to GNFT.
Can you provide the valuation status for GENFIT-ADR?
ChartMill assigns a valuation rating of 0 / 10 to GENFIT-ADR (GNFT). This can be considered as Overvalued.
Can you provide the profitability details for GENFIT-ADR?
GENFIT-ADR (GNFT) has a profitability rating of 2 / 10.
Can you provide the financial health for GNFT stock?
The financial health rating of GENFIT-ADR (GNFT) is 3 / 10.